Literature DB >> 29089354

Calculating the individual probability of successful ocriplasmin treatment in eyes with VMT syndrome: a multivariable prediction model from the EXPORT study.

Christoph Paul1, Christine Heun1, Hans-Helge Müller2, Hans Hoerauf3, Nicolas Feltgen3, Joachim Wachtlin4, Hakan Kaymak5, Stefan Mennel6, Michael Janusz Koss7,8, Sascha Fauser9, Mathias M Maier10, Ricarda G Schumann11, Simone Mueller12, Petrus Chang12, Steffen Schmitz-Valckenberg12, Sara Kazerounian13, Peter Szurman13, Albrecht Lommatzsch14, Thomas Bertelmann3,15.   

Abstract

BACKGROUND/AIMS: To evaluate predictive factors for the treatment success of ocriplasmin and to use these factors to generate a multivariate model to calculate the individual probability of successful treatment.
METHODS: Data were collected in a retrospective, multicentre cohort study. Patients with vitreomacular traction (VMT) syndrome without a full-thickness macular hole were included if they received an intravitreal injection (IVI) of ocriplasmin. Five factors (age, gender, lens status, presence of epiretinal membrane (ERM) formation and horizontal diameter of VMT) were assessed on their association with VMT resolution. A multivariable logistic regression model was employed to further analyse these factors and calculate the individual probability of successful treatment.
RESULTS: 167 eyes of 167 patients were included. Univariate analysis revealed a significant correlation to VMT resolution for all analysed factors: age (years) (OR 0.9208; 95% CI 0.8845 to 0.9586; p<0.0001), gender (male) (OR 0.480; 95% CI 0.241 to 0.957; p=0.0371), lens status (phakic) (OR 2.042; 95% CI 1.054 to 3.958; p=0.0344), ERM formation (present) (OR 0.384; 95% CI 0.179 to 0.821; p=0.0136) and horizontal VMT diameter (µm) (OR 0.99812; 95% CI 0.99684 to 0.99941, p=0.0042). A significant multivariable logistic regression model was established with age and VMT diameter.
CONCLUSION: Known predictive factors for VMT resolution after ocriplasmin IVI were confirmed in our study. We were able to combine them into a formula, ultimately allowing the calculation of an individual probability of treatment success with ocriplasmin in patients with VMT syndrome without FTHM. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  diagnostic tests/investigation; macula; retina; treatment medical; vitreous

Mesh:

Substances:

Year:  2017        PMID: 29089354     DOI: 10.1136/bjophthalmol-2017-310874

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  5 in total

1.  Comparison of the horizontal diameter to a modeled area of traction in eyes with vitreomacular traction: is the diameter close enough to the truth?

Authors:  Christoph Paul; P Krug; H H Müller; J Wachtlin; S Mennel; S Müller; S Schmitz-Valckenberg; T Bertelmann; R G Schumann
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-06-28       Impact factor: 3.117

2.  Predicting the individual probability of macular hole closure following intravitreal ocriplasmin injections for vitreomacular traction release using baseline characteristics.

Authors:  Thomas Bertelmann; Lars Berndzen; Thomas Raber; Sebastian Pfeiffer; Andreas Leha; Christoph Paul; Nicolas Feltgen; Sebastian Bemme
Journal:  Sci Rep       Date:  2021-12-16       Impact factor: 4.379

3.  Calculating the individual probability of successful ocriplasmin treatment in eyes with vitreomacular traction-Validation and refinement of a multivariable prediction model.

Authors:  Christoph Paul; Hans-Helge Müller; Thomas Raber; Thomas Bertelmann
Journal:  PLoS One       Date:  2022-07-25       Impact factor: 3.752

4.  Effectiveness of ocriplasmin in real-world settings: A systematic literature review, meta-analysis, and comparison with randomized trials.

Authors:  Arshad M Khanani; Ryan N Constantine; Koenraad H Blot; Benedicte Lescrauwaet; Peter Szurman
Journal:  Acta Ophthalmol       Date:  2020-12-26       Impact factor: 3.761

5.  OCRIPLASMIN FOR VITREOMACULAR TRACTION IN CLINICAL PRACTICE: The INJECT Study.

Authors:  David H W Steel; Niall Patton; Theodor Stappler; Niral Karia; Hans Hoerauf; Nishal Patel; Joachim Wachtlin; Thomas Raber; Petra Kozma-Wiebe
Journal:  Retina       Date:  2021-02-01       Impact factor: 3.975

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.